Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Wei Liu, Lei Zhang, Zhiming Xiu, Jian Guo, Liye Wang, Yue Zhou, Yang Jiao, Meiyan Sun & Jianhui Cai. (2020) Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer. OncoTargets and Therapy 13, pages 7229-7241.
Read now
Read now
Articles from other publishers (23)
Rushan Sulimanov, Konstantin Koshelev, Vladimir Makarov, Alexandre Mezentsev, Mikhail Durymanov, Lilian Ismail, Komal Zahid, Yegor Rumyantsev & Ilya Laskov. (2023) Mathematical Modeling of Non-Small-Cell Lung Cancer Biology through the Experimental Data on Cell Composition and Growth of Patient-Derived Organoids. Life 13:11, pages 2228.
Crossref
Crossref
Zhuo Li, Weihua Li & Liyan Xue. (2023) Primary pulmonary hyalinizing clear cell carcinoma with vocal-cord squamous cell carcinoma: a case report with systematic review. Diagnostic Pathology 18:1.
Crossref
Crossref
Stephanie G C Kroeze, Matea Pavic, Karin Stellamans, Yolande Lievens, Carlotta Becherini, Marta Scorsetti, Filippo Alongi, Umberto Ricardi, Barbara Alicja Jereczek-Fossa, Paulien Westhoff, Jasna But-Hadzic, Joachim Widder, Xavier Geets, Samuel Bral, Maarten Lambrecht, Charlotte Billiet, Igor Sirak, Sara Ramella, Ivaldi Giovanni Battista, Sergi Benavente, Almudena Zapatero, Fabiola Romero, Thomas Zilli, Kaouthar Khanfir, Hossein Hemmatazad, Berardino de Bari, Desiree N Klass, Shaukat Adnan, Heike Peulen, Juan Salinas Ramos, Michiel Strijbos, Sanjay Popat, Piet Ost & Matthias Guckenberger. (2023) Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium. The Lancet Oncology 24:3, pages e121-e132.
Crossref
Crossref
Xin Wu, Yu Gao, Miyuan Wang, Hongye Peng, Di Zhang, Biyuan Qin, Liang Pan & Guolong Zhu. (2023) Atherosclerosis indexes and incident T2DM in middle-aged and older adults: evidence from a cohort study. Diabetology & Metabolic Syndrome 15:1.
Crossref
Crossref
杰 陈. (2023) Research Progress Related to Immunotherapy for Liver Metastasis of Non-Small Cell Lung Cancer. Advances in Clinical Medicine 13:06, pages 10329-10334.
Crossref
Crossref
Zhe Huang, Chunhua Zhou, Yi Xiong, Feng Yang, Fanxu Zeng, Wenjuan Jiang, Yongchang Zhang, Haiyan Yang, Li Liu, Liang Zeng, Nong Yang & Zhan Wang. (2022) PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study. Frontiers in Oncology 12.
Crossref
Crossref
Taihang Shao, Mingye Zhao, Leyi Liang & Wenxi Tang. (2022) A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. Frontiers in Immunology 13.
Crossref
Crossref
Mingye Zhao, Taihang Shao, Yinan Ren, Caicun Zhou & Wenxi Tang. (2022) Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Bao-Dong Qin, Xiao-Dong Jiao, Yan Wang, Ying Wu, Yan Ling, Ke Liu & Yuan-Sheng Zang. (2022) Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC. Lung Cancer 170, pages 91-97.
Crossref
Crossref
Yasuyuki Ikezawa, Hidenori Mizugaki, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Mototsugu Shimokawa & Satoshi Oizumi. (2022) Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression. Cancer Science 113:6, pages 2109-2117.
Crossref
Crossref
Yingkai Chen, Shizhou Kang & Ming Yan. (2022) Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis. Pharmacology Research & Perspectives 10:3.
Crossref
Crossref
Longqing Li, Yang Wang, Xuanhong He, Zhuangzhuang Li, Minxun Lu, Taojun Gong, Qing Chang, Jingqi Lin, Chuang Liu, Yi Luo, Li Min, Yong Zhou & Chongqi Tu. (2022) Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma. Frontiers in Immunology 13.
Crossref
Crossref
Suji Udayakumar, Ambica Parmar, Natasha B. Leighl, Louis Everest, Vanessa S. Arciero, Seanthel Delos Santos, Amanda Rahmadian, Mark K. Doherty & Kelvin K.W. Chan. (2022) Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology 173, pages 103660.
Crossref
Crossref
Chunyang Zhou, Minghao Li, Zijian Wang, Dianzheng An & Baosheng Li. (2022) Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis. International Immunopharmacology 102, pages 108353.
Crossref
Crossref
Ramon Andrade Bezerra De Mello, Rafael Voscaboinik, João Vittor Pires Luciano, Rafaela Vilela Cremonese, Giovanna Araujo Amaral, Pedro Castelo-Branco & Georgios Antoniou. (2021) Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers 14:1, pages 122.
Crossref
Crossref
Ziyang Mao, Panpan Jiang, Yajuan Zhang, Yanlin Li, Xiaohui Jia, Qinyang Wang, Min Jiao, Lili Jiang, Yuan Shen & Hui Guo. (2021) First‐line immune‐based combination therapies for advanced non‐small cell lung cancer: A Bayesian network meta‐analysis. Cancer Medicine 10:24, pages 9139-9155.
Crossref
Crossref
Patricia Rich, R Brian Mitchell, Eric Schaefer, Paul R Walker, John W Dubay, Jason Boyd, David Oubre, Ray Page, Mazen Khalil, Suman Sinha, Scott Boniol, Hafez Halawani, Edgardo S Santos, Warren Brenner, James M Orsini, Emily Pauli, Jonathan Goldberg, Andrea Veatch, Mitchell Haut, Bassam Ghabach, Savita Bidyasar, Maria Quejada, Waseemullah Khan, Kan Huang, Linda Traylor & Wallace Akerley. (2021) Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer. Journal for ImmunoTherapy of Cancer 9:10, pages e002989.
Crossref
Crossref
Roy Herbst, Jacek Jassem, Seye Abogunrin, Daniel James, Rachael McCool, Rossella Belleli, Giuseppe Giaccone & Filippo De Marinis. (2021) A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. Frontiers in Oncology 11.
Crossref
Crossref
Ya Chen, Yanan Wang, Zhengyu Yang, Minjuan Hu, Yanwei Zhang, Fangfei Qian, Wei Zhang, Bo Zhang & Baohui Han. (2021) Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study. Frontiers in Oncology 11.
Crossref
Crossref
Margarita Majem, Manuel Cobo, Dolores Isla, Diego Marquez-Medina, Delvys Rodriguez-Abreu, Joaquín Casal-Rubio, Teresa Moran-Bueno, Reyes Bernabé-Caro, Diego Pérez-Parente, Pedro Ruiz-Gracia, Marta Marina Arroyo & Luis Paz-Ares. (2021) PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. Journal of Clinical Medicine 10:7, pages 1365.
Crossref
Crossref
Fei Zhou, Meng Qiao & Caicun Zhou. (2020) The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cellular & Molecular Immunology 18:2, pages 279-293.
Crossref
Crossref
Lei Sheng, Jing Gao, Qian Xu, Xue Zhang, Miao Huang, Xin Dai, Song Li & Lian Liu. (2021) Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. Therapeutic Advances in Medical Oncology 13, pages 175883592110185.
Crossref
Crossref
Taichiro Goto, Kei Kunimasa, Yosuke Hirotsu, Takahiro Nakagomi, Yujiro Yokoyama, Rumi Higuchi, Sotaro Otake, Toshio Oyama, Kenji Amemiya, Hitoshi Mochizuki & Masao Omata. (2020) Association of Mutation Profiles with Postoperative Survival in Patients with Non–Small Cell Lung Cancer. Cancers 12:11, pages 3472.
Crossref
Crossref